Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Current Deferred Revenue (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Current Deferred Revenue for 14 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 45.52% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, down 45.52% year-over-year, with the annual reading at $1.1 million for FY2025, 45.52% down from the prior year.
  • Current Deferred Revenue hit $1.1 million in Q4 2025 for Ironwood Pharmaceuticals, up from $1.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $2.6 million in Q4 2023 to a low of $978000.0 in Q2 2025.
  • Historically, Current Deferred Revenue has averaged $1.6 million across 3 years, with a median of $1.5 million in 2025.
  • Biggest five-year swings in Current Deferred Revenue: fell 22.44% in 2024 and later tumbled 45.52% in 2025.
  • Year by year, Current Deferred Revenue stood at $2.6 million in 2023, then dropped by 22.44% to $2.0 million in 2024, then plummeted by 45.52% to $1.1 million in 2025.
  • Business Quant data shows Current Deferred Revenue for IRWD at $1.1 million in Q4 2025, $1.0 million in Q3 2025, and $978000.0 in Q2 2025.